PRMT1 and acute myeloid leukemia: Inhibition of ATG4B enhances PRMT1‐MRE11‐mediated DNA damage responses, promotes S‐phase checkpoint activation, and induces robust S‐to‐G2/M cell cycle arrest in AML cells.